Corrigendum to "Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia". . Am J Hematol 2023 Mar 24. doi: 10.1002/ajh.26894.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Corrigendum to "Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia". Am J Hematol 2023 Mar 24. doi: 10.1002/ajh.26894.
PMID: 36960612